Faes Farma, S.A.

FAE

ES0134950F36

Pharmaceuticals

Delayed BME Other stock markets 09:24:57 2024-04-19 am EDT			5-day change	1st Jan Change
3.165 ^EUR	-0.31%		+0.16%	0.00%

Feb. 27	FAES FARMA : Q4 profitability exceeded expectations
Feb. 27	Faes Farma, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

FAES Farma SA : Statement 24/01/2012 (19 k). Bilastine's launch in Brazil.

January 25, 2012 at 08:26 am EST

MarketScreener.com By The editorial team

TAKEDA NYCOMED, one of the first ten pharmaceutical companies worldwide, with an important presence in the respiratory area, has started to market bilastine in Brazil. Bilastine is an antihistaminic, license from FAES FARMA, S.A.

Brazil is the biggest pharmaceutical market in Latin America, with annual sales in the allergy area of over 100 million euro.

24th of January 2012.

distribué par

Ce noodl a été diffusé par Faes Farma SA et initialement mise en ligne sur le site http://www.faes.es. La version originale est disponible ici.

Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-25 14:17:52 PM et restera accessible depuis ce lien permanent.

Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité.

Documents associés

Statement 24/01/2012 (19 k). Bilastine's launch in Brazil.

Latest news about Faes Farma, S.A.

FAES FARMA : Q4 profitability exceeded expectations	Feb. 27
Faes Farma, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
FAES FARMA : Mixed Q3; markets need more from Faes to be convinced	23-10-25
Faes Farma, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-14	CI
FAES FARMA : A soft Q2, as expected; guidance maintained	23-08-01
Faes Farma, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-28	CI
FAES FARMA : Increased R&D focus and inflationary pressures to hold back near-to-medium term earnings	23-07-12
FAES FARMA : A healthy start to 2023	23-05-08
Faes Farma, S.A. completed the acquisition of NovoSci.	23-05-02	CI
Faes Farma, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-02	CI
FAES FARMA : 2022 guidance met + positive view maintained	23-03-06
Faes Farma, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Faes Farma, S.A. agreed to acquire NovoSci.	23-01-11	CI
Roche’s Alzheimer’s failure has sector-wide implications	22-11-14
Faes Farma, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-02	CI
FAES FARMA : Soft Q3, but 2022 guidance maintained	22-10-28
FAES FARMA : Another stronger quarter but maintained full-year outlook	22-08-01
Faes Farma, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-28	CI
Faes Farma, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-28	CI
FAES FARMA : Strong Q1; but some moderation lies ahead	22-05-02
Faes Farma, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
FAES FARMA : A strong Q4 sums up a decent 2021	22-03-02
Faes Farma, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI
FAES FARMA : An overall strong Q3	21-11-02
Faes Farma, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-25	CI

Chart Faes Farma, S.A.

Duration

Period

More charts

Company Profile

Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Companyâs research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FAES FARMA : Q4 profitability exceeded expectations

February 27, 2024 at 11:00 am EST

More Strategies

Ratings for Faes Farma, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

3.175 EUR

Average target price

3.708 EUR

Spread / Average Target

+16.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FAES FARMA, S.A.	0.00%	1.05B
ELI LILLY AND COMPANY	+27.97%	672B
NOVO NORDISK A/S	+23.72%	550B
JOHNSON & JOHNSON	-7.02%	351B
MERCK & CO., INC.	+14.85%	317B
ABBVIE INC.	+6.25%	292B
ASTRAZENECA PLC	+2.17%	211B
NOVARTIS AG	-0.29%	203B
PFIZER, INC.	-11.81%	144B
AMGEN INC.	-8.80%	141B

Other Pharmaceuticals

Faes Farma, S.A.

Equities

FAE

ES0134950F36

Pharmaceuticals

FAES Farma SA : Statement 24/01/2012 (19 k). Bilastine's launch in Brazil.

EPS Revisions

Quarterly revenue - Rate of surprise